Company intelligence / Profile preview

Promiss

Ownership: Private
Development stage: Preclinical

Overview

PROMISS Diagnostics is developing innovative, accessible diagnostic tools aimed at early-stage cancer detection, with a primary focus on ovarian cancer. The company leverages advanced analytics and applied science to extract diagnostic value from standard blood tests. Clinical results have not been published in detail; the company is still in the development and validation phase

Therapeutic areas: Oncology
Modalities: Diagnostic testAnalytics platform (applied science, blood-based diagnostics)
Industry: Protein Biomarker Diagnostics

Partnerships

Not specifically listed; mentions of clinical and strategic partnerships but no named partners

Beyond the preview

Go deeper on Promiss.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Promiss.

Explore the full profile